UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Management of refractory heart failure with reduced ejection fraction

Authors
Shannon M Dunlay, MD, MS
Wilson S Colucci, MD
Section Editor
Stephen S Gottlieb, MD
Deputy Editor
Susan B Yeon, MD, JD, FACC

INTRODUCTION

Although the majority of patients with heart failure with reduced ejection fraction (HFrEF) respond to optimal medical therapy, some patients do not improve or experience rapid and repetitive recurrences of symptoms. These patients have symptoms at rest or on minimal exertion and often require repeated prolonged hospitalizations for intensive management. Patients with chronic HF with severe symptoms despite maximum guideline-directed medical therapy are classified by the American College of Cardiology Foundation/American Heart Association as having stage D HF [1].

Specialized strategies for patients with refractory HFrEF include intravenous vasodilator and inotropic therapy, ultrafiltration, mechanical circulatory support, surgery including cardiac transplantation, and palliative care.

An overview of therapies used to treat refractory HFrEF is presented here. General treatment strategies for HFrEF and treatment of HF with preserved ejection fraction (HFpEF) are discussed separately. (See "Overview of the therapy of heart failure with reduced ejection fraction" and "Treatment and prognosis of heart failure with preserved ejection fraction".)

GENERAL MANAGEMENT

The general management of patients with refractory heart failure with reduced ejection fraction (HFrEF) includes optimizing all standard evidence-based drug and device therapy as well as volume management. Referral to a program with expertise in the management of refractory HF and advanced therapies is recommended. Monitoring is indicated to assess patient status as well as the effects of therapy.

Optimizing evidence-based therapy — The first step in managing suspected refractory HFrEF is to confirm that all conventional evidence-based strategies (including pharmacologic therapy and device therapy such as cardiac resynchronization therapy and implantable cardioverter-defibrillator) have been optimally employed and that contributing conditions have been recognized and treated. Recommendations for patients with other stages of HF are also appropriate for patients with end-stage (stage D) HF. (See "Overview of the therapy of heart failure with reduced ejection fraction" and "Primary prevention of sudden cardiac death in heart failure and cardiomyopathy" and "Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy" and "Cardiac resynchronization therapy in heart failure: Indications".)

                        

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Mar 2017. | This topic last updated: Mar 20, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:e147.
  2. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:e240.
  3. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297:1332.
  4. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297:1319.
  5. Shuhaiber JH, Moore J, Dyke DB. The effect of transplant center volume on survival after heart transplantation: a multicenter study. J Thorac Cardiovasc Surg 2010; 139:1064.
  6. Weiss ES, Meguid RA, Patel ND, et al. Increased mortality at low-volume orthotopic heart transplantation centers: should current standards change? Ann Thorac Surg 2008; 86:1250.
  7. Shah N, Chothani A, Agarwal V, et al. Impact of Annual Hospital Volume on Outcomes after Left Ventricular Assist Device (LVAD) Implantation in the Contemporary Era. J Card Fail 2016; 22:232.
  8. Steimle AE, Stevenson LW, Chelimsky-Fallick C, et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation 1997; 96:1165.
  9. Drazner MH, Solomon MA, Thompson B, Yancy CW. Tailored therapy using dobutamine and nitroglycerin in advanced heart failure. Am J Cardiol 1999; 84:941.
  10. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005; 294:1625.
  11. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997; 350:1417.
  12. Stevenson LW. Are hemodynamic goals viable in tailoring heart failure therapy? Hemodynamic goals are relevant. Circulation 2006; 113:1020.
  13. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:1810.
  14. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367:2296.
  15. Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013; 310:2533.
  16. Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 1999; 138:247.
  17. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287:1541.
  18. Krell MJ, Kline EM, Bates ER, et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 1986; 112:787.
  19. Dies, F, Krell, MJ, Whitlow, P. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation (abstract) 1986; 74 (Suppl II):38.